| __timestamp | Eli Lilly and Company | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 2999000 |
| Thursday, January 1, 2015 | 6533000000 | 10393000 |
| Friday, January 1, 2016 | 6452000000 | 15994000 |
| Sunday, January 1, 2017 | 6588100000 | 26975000 |
| Monday, January 1, 2018 | 5975100000 | 39509000 |
| Tuesday, January 1, 2019 | 6213800000 | 48869000 |
| Wednesday, January 1, 2020 | 6121200000 | 42510000 |
| Friday, January 1, 2021 | 6431600000 | 46105000 |
| Saturday, January 1, 2022 | 6440400000 | 50513000 |
| Sunday, January 1, 2023 | 6941200000 | 51292000 |
| Monday, January 1, 2024 | 8593800000 |
Cracking the code
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Eli Lilly and Company, a titan in the industry, has consistently allocated substantial resources to SG&A, with a notable 5% increase from 2022 to 2023. In contrast, Wave Life Sciences Ltd., a smaller player, has shown a remarkable growth trajectory, with SG&A expenses surging by over 1,600% since 2014. This stark contrast highlights the differing strategies of a well-established giant versus an emerging innovator. While Eli Lilly's spending reflects its expansive operations, Wave Life Sciences' increasing investment underscores its aggressive growth ambitions. As the pharmaceutical landscape evolves, these spending patterns offer a glimpse into the strategic priorities of these companies, shaping their future in a competitive market.
Eli Lilly and Company or Gilead Sciences, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Incyte Corporation
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Wave Life Sciences Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? Insmed Incorporated or Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Wave Life Sciences Ltd.
Comparing SG&A Expenses: Cytokinetics, Incorporated vs Wave Life Sciences Ltd. Trends and Insights
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights